ClinicalTrials.gg
RecruitingNCT06816095OzoGynEpigenUpdated Sep 25, 2026

Gene and Molecular Pathways of Ozone Treatment Response in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Cancer Treatment

An observational study in Chronic Pelvic Pain Syndrome (CPPS), Radiation-Induced Disorder and Radiotherapy Side Effects, sponsored by Bernardino Clavo, MD, PhD. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Bernardino Clavo, MD, PhD · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Sep 25, 2026Sponsor changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
Female
01

Study summary

Gynecological cancers, including those affecting the ovaries, uterus, and cervix, represent a significant health burden for women. While survival rates have improved, many women experience chronic pelvic pain secondary to cancer treatment, especially radiotherapy and chemotherapy. This treatment-induced pelvic pain can be of difficult management and significantly affects patients' quality of life.

In our experience, ozone therapy has emerged as a promising complementary treatment for pain relief in patients with chronic diseases, including side effects of cancer treatment. However, the genetic and epigenetic mechanisms influencing its effectiveness have not yet been thoroughly studied.

The aim of this prospective study is to analyze how ozone therapy modulates the expression of certain genes and its impact on epigenetic clocks, which could help predict pain response.

Read the detailed description

While survival rates of gynecological cancers have improved, many women experience chronic pelvic pain as a consequence of cancer treatment, particularly radiotherapy and chemotherapy. This persistent pain often has neuropathic characteristics, and it can be challenging to manage, negatively impacting physical and emotional well-being and quality of life.

Conventional pain management strategies for these patients often provide limited relief. In our experience, ozone therapy has emerged as a promising option for managing chronic pain in various conditions, including side effects of cancer treatment.

While the clinical benefits of ozone therapy have been observed in preliminary studies, the underlying molecular mechanisms underlying its analgesic effect remain largely unknown. Understanding how ozone therapy influences gene expression and epigenetic modifications could facilitate the identification of genes involved in the differential response to ozone therapy and a potential way for personalized strategies for pain treatment.

The aim of this prospective study is to analyze how ozone therapy modulates the expression of certain genes and its impact on epigenetic clocks, which could help predict pain response.

Primary Objectives:

In patients with gynecological tumors treated by radiotherapy/chemotherapy, To evaluate

  • among patients with or without chronic pelvic pain induced by treatment.
  • before and after ozone treatment in those patients treated because of pelvic pain induced by radiotherapy/chemotherapy.

The potential differences in:

  1. Gene expression.
  2. Biological age based on epigenetic clocks:

Secondary Objectives:

Evaluate in those patients the potential relationship between gene expression and epigenetic clocks with:

  1. Grade of toxicity
  2. Pain score
  3. Health-related quality of life,
  4. Biochemical markers of oxidative stress and inflammation.

Trial Design:

This observational and prospective study will analyze data from two groups of patients with gynecological tumors treated with radiotherapy/chemotherapy:

  • A group of patients with chronic pelvic pain secondary to radiotherapy-chemotherapy, submitted to our Chronic Pain Unit for compassionate/palliative ozone treatment.
  • A group of patients without secondary chronic pelvic pain.

Trial Population:

Adult women (≥ 18 years old) with gynecological tumors treated with radiotherapy-chemotherapy. They will be analyzed into two different groups of patients:

  • A group of patients with chronic pelvic pain secondary to radiotherapy-chemotherapy, submitted to our Chronic Pain Unit for compassionate/palliative ozone treatment.
  • A group of patients without secondary chronic pelvic pain.

Intervention. No intervention. The management of patients will be the standard of care in our hospital.

Study Duration:

The primary completion date is planned for 14/February/2027. The study completion date is planned for 14/August/2027

02

Conditions studied

  • Chronic Pelvic Pain Syndrome (CPPS)
  • Radiation-Induced Disorder
  • Radiotherapy Side Effects
  • Side Effect of Chemotherapy
  • Gynecological Cancers

Keywords

  • Radiation-Induced Disorder
  • Radiotherapy Side Effects
  • Cancer survivors
  • Chronic Pelvic Pain Syndrome (CPPS)
  • Gynecological Cancers
  • gene expression
  • epigenetic clocks
  • side effects of cancer treatment
  • Toxicity of chemotherapy
  • Ozone therapy
  • Quality of Life
  • oxidative stress
03

In context

Lead sponsor

Bernardino Clavo, MD, PhD is the lead sponsor of 10 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult women (≥18 years) with gynecological tumors treated with radiotherapy-chemotherapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult women (>=18 years old) with gynecological tumors treated with radiotherapy-chemotherapy.
  • Cancer disease is stable or in remission.
  • > = 6 months.
  • Patients included in the group of patients with pelvic pain must have a clinical, radiological, endoscopic, or histopathological diagnosis that their pain is not secondary to the oncological process.
  • Patients included in the group of patients with pelvic pain must have pain for >= 3 months duration, with an intensity >= 3 on the Visual Analog Scale (VAS), or classified as toxicity >= Grade-2 of the v.5.0 of the National Cancer Institute of the USA.
  • Signed and dated specific to this study.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years old.
  • Severe psychiatric disorders.
  • Inability to complete the quality of life questionnaires.
  • Active neoplasia requiring recent initiation (\< 3 months) of systemic or local treatment.
  • (for any reason) \< 6 months.
  • Failure to meet all inclusion criteria
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Treated patients, without secondary pain

    Patients with gynecological tumors, treated with radiotherapy/chemotherapy, without chronic pelvic pain.

  • Treated patients, with chronic pelvic pain

    Patients with gynecological tumors, treated with radiotherapy/chemotherapy, with chronic pelvic pain, submitted to our Chronic Pain Unit for compassionate/palliative ozone treatment.

06

What researchers measure

Primary outcomes

  1. Differences in gene expression among patients with or without chronic pelvic pain induced by radiotherapy/chemotherapy.

    Differences (among patients with or without chronic pelvic pain induced by radiotherapy/chemotherapy) in gene expression profile.

    Time frame: At 0 week

  2. Changes (from baseline) in gene expression at the end of ozone treatment.

    Changes (from baseline) in gene expression profile, after ozone treatment.

    Time frame: At 16 weeks

  3. Differences in biological age based on epigenetic clocks among patients with or without chronic pelvic pain induced by radiotherapy/chemotherapy

    Differences (among patients with or without chronic pain induced by radiotherapy/chemotherapy) in the biological age based on epigenetic clocks.

    Time frame: At 0 week.

  4. Changes (from baseline) in the biological age based on epigenetic clocks, after ozone treatment

    Changes (from baseline) in the biological age based on epigenetic clocks, after ozone treatment

    Time frame: At 16 weeks.

Secondary outcomes

  1. Differences in the grade of toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) v.5.0 scale among patients with or without chronic pain induced by radiotherapy/chemotherapy

    Differences (among patients with or without chronic pain induced by radiotherapy/chemotherapy) in the grade of toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) v.5.0 scale (from the National Cancer Institute of EEUU). Range from: Grade = (asymptomatic or mild symptoms) to Grade 3 (severe symptoms, limiting self-care activities in daily life).

    Time frame: At 0 week.

  2. Changes (from baseline) in the grade of toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) v.5.0 scale, after ozone treatment.

    Changes (from baseline) in the grade of toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) v.5.0 scale (from the National Cancer Institute of EEUU). Range from: Grade = (asymptomatic or mild symptoms) to Grade 3 (severe symptoms, limiting self-care activities in daily life).

    Time frame: At 16 weeks.

  3. Differences in pain score according to the visual analog scale (VAS) among patients with or without chronic pain induced by radiotherapy/chemotherapy

    Self-reported evaluation of the severity of pain according to the VAS, scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").

    Time frame: At 0 week.

  4. Change (from baseline) in pain score according to the visual analog scale (VAS), after ozone treatment.

    Self-reported evaluation of the severity of pain according to the VAS, scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").

    Time frame: At 16 weeks.

  5. Differences in "Quality of Life" (using the EQ-5D-5L questionnaire) self-perceived by patients among patients with or without chronic pain induced by radiotherapy/chemotherapy.

    Self-reported evaluation of: a) 5 physical and emotional items scored in five levels, from 1 (Best: I have no problem) to 5 (worst: I have an extreme problem or I am unable to…) and b) additional self-assessment of health by a visual analog scale (0 = worst health patient can imagine, 100 = best health patient can imagine).

    Time frame: At 0 week.

  6. Changes (from baseline) in "Quality of Life" (using the EQ-5D-5L questionnaire) self-perceived by patients, after ozone treatment.

    Self-reported evaluation of: a) 5 physical and emotional items scored in five levels, from 1 (Best: I have no problem) to 5 (worst: I have an extreme problem or I am unable to…) and b) additional self-assessment of health by a visual analog scale (0 = worst health patient can imagine, 100 = best health patient can imagine).

    Time frame: At 16 weeks.

  7. Differences in biochemical parameters of oxidative stress among patients with or without chronic pain induced by radiotherapy/chemotherapy.

    Differences in serum levels of antioxidants and free radicals.

    Time frame: At 0 week.

  8. Changes (from baseline) in biochemical parameters of oxidative stress, after ozone treatment.

    Changes in serum levels of antioxidants and free radicals.

    Time frame: At 16 weeks.

  9. Differences in biochemical parameters of inflammation among patients with or without chronic pain induced by radiotherapy/chemotherapy.

    Differences in serum levels of pro-inflammatory cytokines.

    Time frame: At 0 week.

  10. Changes (from baseline) in biochemical parameters of inflammation, after ozone treatment.

    Changes in serum levels of pro-inflammatory cytokines.

    Time frame: At 16 weeks.

07

Study locations

1 of 1 sites recruiting
  • Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC)
    Las Palmas, Las Palmas 35019, Spain
    Recruiting
    • Bernardino Clavo, MD, PhD · Contactbernardinoclavo@gmail.com · 34928449278
    • Francisco Rodríguez-Esparragón, BSc, PhD · Contactafrodesp@gmail.com · 34928449288
    • Sara Cazorla-Rivero, BSc, PhD · Principal investigator
    • Mario Federico, MD, PhD · Principal investigator
08

References and documents

Publications

  • Tricarico G, Travagli V. The Relationship between Ozone and Human Blood in the Course of a Well-Controlled, Mild, and Transitory Oxidative Eustress. Antioxidants (Basel). 2021 Dec 4;10(12):1946. doi: 10.3390/antiox10121946. PubMed 34943049 ↗
  • Hidalgo-Tallon FJ, Torres-Morera LM, Baeza-Noci J, Carrillo-Izquierdo MD, Pinto-Bonilla R. Updated Review on Ozone Therapy in Pain Medicine. Front Physiol. 2022 Feb 23;13:840623. doi: 10.3389/fphys.2022.840623. eCollection 2022. PubMed 35283802 ↗
  • Galie M, Covi V, Tabaracci G, Malatesta M. The Role of Nrf2 in the Antioxidant Cellular Response to Medical Ozone Exposure. Int J Mol Sci. 2019 Aug 17;20(16):4009. doi: 10.3390/ijms20164009. PubMed 31426459 ↗
  • Clavo B, Santana-Rodriguez N, Llontop P, Gutierrez D, Ceballos D, Mendez C, Rovira G, Suarez G, Rey-Baltar D, Garcia-Cabrera L, Martinez-Sanchez G, Fiuza D. Ozone Therapy in the Management of Persistent Radiation-Induced Rectal Bleeding in Prostate Cancer Patients. Evid Based Complement Alternat Med. 2015;2015:480369. doi: 10.1155/2015/480369. Epub 2015 Aug 18. PubMed 26357522 ↗
  • Clavo B, Rodriguez-Esparragon F, Rodriguez-Abreu D, Martinez-Sanchez G, Llontop P, Aguiar-Bujanda D, Fernandez-Perez L, Santana-Rodriguez N. Modulation of Oxidative Stress by Ozone Therapy in the Prevention and Treatment of Chemotherapy-Induced Toxicity: Review and Prospects. Antioxidants (Basel). 2019 Nov 26;8(12):588. doi: 10.3390/antiox8120588. PubMed 31779159 ↗
  • Clavo B, Navarro M, Federico M, Borrelli E, Jorge IJ, Ribeiro I, Rodriguez-Melcon JI, Carames MA, Santana-Rodriguez N, Rodriguez-Esparragon F. Long-Term Results with Adjuvant Ozone Therapy in the Management of Chronic Pelvic Pain Secondary to Cancer Treatment. Pain Med. 2021 Sep 8;22(9):2138-2141. doi: 10.1093/pm/pnaa459. No abstract available. PubMed 33738491 ↗
  • Clavo B, Navarro M, Federico M, Borrelli E, Jorge IJ, Ribeiro I, Rodriguez-Melcon JI, Carames MA, Santana-Rodriguez N, Rodriguez-Esparragon F. Ozone Therapy in Refractory Pelvic Pain Syndromes Secondary to Cancer Treatment: A New Approach Warranting Exploration. J Palliat Med. 2021 Jan;24(1):97-102. doi: 10.1089/jpm.2019.0597. Epub 2020 May 5. PubMed 32379556 ↗
  • Clavo B, Rodriguez-Abreu D, Galvan S, Federico M, Martinez-Sanchez G, Ramallo-Farina Y, Antonelli C, Benitez G, Rey-Baltar D, Jorge IJ, Rodriguez-Esparragon F, Serrano-Aguilar P. Long-term improvement by ozone treatment in chronic pain secondary to chemotherapy-induced peripheral neuropathy: A preliminary report. Front Physiol. 2022 Aug 30;13:935269. doi: 10.3389/fphys.2022.935269. eCollection 2022. PubMed 36111149 ↗
  • Clavo B, Martinez-Sanchez G, Rodriguez-Esparragon F, Rodriguez-Abreu D, Galvan S, Aguiar-Bujanda D, Diaz-Garrido JA, Canas S, Torres-Mata LB, Fabelo H, Tellez T, Santana-Rodriguez N, Fernandez-Perez L, Marrero-Callico G. Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial. Int J Mol Sci. 2021 Mar 10;22(6):2802. doi: 10.3390/ijms22062802. PubMed 33802143 ↗
  • Clavo B, Canovas-Molina A, Ramallo-Farina Y, Federico M, Rodriguez-Abreu D, Galvan S, Ribeiro I, Marques da Silva SC, Navarro M, Gonzalez-Beltran D, Diaz-Garrido JA, Cazorla-Rivero S, Rodriguez-Esparragon F, Serrano-Aguilar P. Effects of Ozone Treatment on Health-Related Quality of Life and Toxicity Induced by Radiotherapy and Chemotherapy in Symptomatic Cancer Survivors. Int J Environ Res Public Health. 2023 Jan 13;20(2):1479. doi: 10.3390/ijerph20021479. PubMed 36674232 ↗
  • Clavo B, Canovas-Molina A, Diaz-Garrido JA, Canas S, Ramallo-Farina Y, Laffite H, Federico M, Rodriguez-Abreu D, Galvan S, Garcia-Lourve C, Gonzalez-Beltran D, Carames MA, Hernandez-Fleta JL, Serrano-Aguilar P, Rodriguez-Esparragon F. Effects of ozone therapy on anxiety and depression in patients with refractory symptoms of severe diseases: a pilot study. Front Psychol. 2023 Aug 4;14:1176204. doi: 10.3389/fpsyg.2023.1176204. eCollection 2023. PubMed 37599784 ↗
  • Clavo B, Rodriguez-Abreu D, Galvan-Ruiz S, Federico M, Canovas-Molina A, Ramallo-Farina Y, Antonilli C, Benitez G, Fabelo H, Garcia-Lourve C, Gonzalez-Beltran D, Jorge IJ, Rodriguez-Esparragon F, Callico GM. Long-Term Effects of Ozone Treatment in Patients with Persistent Numbness and Tingling Secondary to Chemotherapy-Induced Peripheral Neuropathy. A Retrospective Study. Integr Cancer Ther. 2025 Jan-Dec;24:15347354241307038. doi: 10.1177/15347354241307038. PubMed 39797612 ↗
  • Bocci VA, Zanardi I, Travagli V. Ozone acting on human blood yields a hormetic dose-response relationship. J Transl Med. 2011 May 17;9:66. doi: 10.1186/1479-5876-9-66. PubMed 21575276 ↗
  • Bocci V, Valacchi G. Nrf2 activation as target to implement therapeutic treatments. Front Chem. 2015 Feb 2;3:4. doi: 10.3389/fchem.2015.00004. eCollection 2015. PubMed 25699252 ↗
  • Bocci V, Borrelli E, Travagli V, Zanardi I. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev. 2009 Jul;29(4):646-82. doi: 10.1002/med.20150. PubMed 19260079 ↗

Individual participant data

Plan to share: Yes — It will be available (after request): Individual participant data (IPD) that underlie the results reported in further articles, after deidentification Data will be available after publication, ending 36 months following article publication. They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. Study protocol Proposals should be directed to: bernardinoclavo@gmail.com To gain access, data requestors will need to sign a data access agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data will be available after publication, ending 36 months following article publication.

Access criteria: Data will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. - Study protocol Proposals should be directed to: bernardinoclavo@gmail.com To gain access, data requestors will need to sign a data access agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2025
First posted
Feb 10, 2025
StartActual
Feb 10, 2025
Primary completionEst.
Feb 14, 2027
CompletionEst.
Aug 14, 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC) · Las Palmas, Spain
Show 1 removed
  • Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC) · Las Palmas, Spain
Sep 25, 2026
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionChanges (from baseline) in "Quality of Life" (using the EQ-5D-5L questionnaire) self-perceived by patients, after ozone treatment.: how it is measured was reworded
  • DescriptionDifferences in "Quality of Life" (using the EQ-5D-5L questionnaire) self-perceived by patients among patients with or without chronic pain induced by radiotherapy/chemotherapy.: how it is measured was reworded
Sep 25, 2026
Sponsor
Collaborators added: Fundación Canaria Instituto de Investigación Sanitaria de Canarias; collaborators removed: Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    1 site added, 1 site removed
    Show site
    • Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC) · Las Palmas, Spain
    Show 1 removed
    • Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC) · Las Palmas, Spain
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionChanges (from baseline) in "Quality of Life" (using the EQ-5D-5L questionnaire) self-perceived by patients, after ozone treatment.: how it is measured was reworded
    • DescriptionDifferences in "Quality of Life" (using the EQ-5D-5L questionnaire) self-perceived by patients among patients with or without chronic pain induced by radiotherapy/chemotherapy.: how it is measured was reworded
    Sponsor Collaborators added: Fundación Canaria Instituto de Investigación Sanitaria de Canarias; collaborators removed: Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias
    + 5 other changes: index terms, identifiers, verification date, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06816095
Lead sponsor
Bernardino Clavo, MD, PhD
Collaborators
Fundación Canaria Instituto de Investigación Sanitaria de Canarias, Fundación DISA, Canary Islands, Spain, Council of Gran Canaria
Responsible party
Bernardino Clavo, MD, PhD (Head of the Research Unit, Hospital Universitario de Gran Canaria Doctor Negrín) — Sponsor-investigator
First posted
Feb 10, 2025
Start date
Feb 10, 2025
Primary completion
Feb 14, 2027 (estimated)
Completion
Aug 14, 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Bernardino Clavo, MD, PhD
Contact
bernardinoclavo@gmail.com
34928449278
Francisco Rodríguez-Esparragón, BSc, PhD
Contact
afrodesp@gmail.com
34928449288
Bernardino Clavo, MD, PhD
study chair · Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain.
Francisco Rodríguez-Esparragón, BSc, PhD
study director · Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain.
Sara Cazorla-Rivero, BSc, PhD
principal investigator · Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain.
Mario Federico, MD, PhD
principal investigator · Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion